China biopharmaceutical: second generation highly selective P2X3 inhibitor approved clinical trial

MGI Tech: Lead Life Science Through Intelligent Innovation

In the dynamic realm of bioscience, MGI Tech Co., Ltd. (MGI) has emerged as a torchbearer, captivating attention with its trailblazing achievements and relentless dedication to innovation.

China's Domestic Games Earn USD 17.3 Billion in Overseas Sales in 2022

The rapid overseas expansion of Chinese domestically-produced games is gaining momentum.

The 20th China-ASEAN Expo: Over RMB 480 Billion of Total Investment Signed

The signing ceremony of the 20th China-ASEAN Expo was held on September 17 in Nanning, Guangxi. A total of 470 investment and cooperation projects were signed at this year's China-ASEAN Expo, with a total investment of RMB 487.3 billion, a record high.

Pharmaceutical Machine Vision Company aocheng Nets Tens of Millions in Round A

EqualOcean has learned that aocheng (Chinese: 奥乘智能), a machine vision inspection company in the pharmaceutical field, has recently closed tens of millions of CNY in round A financing.

CTTQ, Ampsourcebio Ink Agreement on Cure for NASH, T2DM

There are more than 95 plus major players and more than 90 plus nonalcoholic steatohepatitis (NASH) pipeline therapies, but none of them has been approved for marketing. Who would survive the competition in the blue-ocean market for NASH?